Phio Pharmaceuticals Corp. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Phio Pharmaceuticals Corp. on January 22, 2019. The report details the execution of a First Amendment to an existing lease agreement for the Company's principal executive offices and laboratory space located at 257 Simarano Drive, Marlborough, Massachusetts.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or margin data. The only specific financial metric disclosed relates to the amended lease agreement:
- Base Rent (Year 1 of Extension): $124,864.78 per annum, payable monthly.
- Rent Escalation: Approximately 3% annual increase thereafter.
- Lease Term Extension: 5 years, commencing April 1, 2019.
Material Changes
The primary material change is the extension of the lease term for the Company's office and laboratory premises. The original lease, dated December 17, 2013, has been amended to extend for five years starting April 1, 2019. The amendment introduces specific termination rights with associated penalties:
- Termination Option 1: March 31, 2021, with six months' rent penalty.
- Termination Option 2: March 31, 2022, with three months' rent penalty.
Outlook, Risks, and Contingencies
The filing does not contain forward-looking guidance, management commentary on financial performance, or a discussion of general business risks. The primary contingency noted is the creation of a direct financial obligation under the amended lease terms. The Company has elected not to use the extended transition period for complying with new accounting standards as an emerging growth company.
Investor Verification Checklist
- Verify the total annual rent obligation starting April 1, 2019 ($124,864.78).
- Confirm the specific termination penalties (6 months vs. 3 months rent) associated with the 2021 and 2022 exit options.
- Review the full text of the First Amendment (Exhibit 10.1) for any additional covenants or conditions not summarized in the 8-K.
- Check subsequent filings for any updates on the Company's cash position to ensure ability to meet the new lease obligations.